185 related articles for article (PubMed ID: 35961838)
1. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.
Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL
J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
Chen CX; Hay JW
Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
[TBL] [Abstract][Full Text] [Related]
4. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
[TBL] [Abstract][Full Text] [Related]
5. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
[TBL] [Abstract][Full Text] [Related]
6. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis.
Marquina C; Lacaze P; Tiller J; Riaz M; Sturm AC; Nelson MR; Ference BA; Pang J; Watts GF; Nicholls SJ; Zoungas S; Liew D; McNeil J; Ademi Z
Eur Heart J; 2022 Sep; 43(34):3243-3254. PubMed ID: 34788414
[TBL] [Abstract][Full Text] [Related]
7. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
[TBL] [Abstract][Full Text] [Related]
8. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
[TBL] [Abstract][Full Text] [Related]
9. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
[TBL] [Abstract][Full Text] [Related]
10. Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis.
Guzauskas GF; Garbett S; Zhou Z; Schildcrout JS; Graves JA; Williams MS; Hao J; Jones LK; Spencer SJ; Jiang S; Veenstra DL; Peterson JF
Ann Intern Med; 2023 May; 176(5):585-595. PubMed ID: 37155986
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness and Return on Investment of a Nationwide Case-Finding Program for Familial Hypercholesterolemia in Children in the Netherlands.
Ademi Z; Norman R; Pang J; Sijbrands E; Watts GF; Hutten BA; Wiegman A
JAMA Pediatr; 2023 Jun; 177(6):625-632. PubMed ID: 37126315
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States.
Guzauskas GF; Jiang S; Garbett S; Zhou Z; Spencer SJ; Snyder SR; Graves JA; Williams MS; Hao J; Peterson JF; Veenstra DL
Genet Med; 2022 May; 24(5):1017-1026. PubMed ID: 35227606
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
[TBL] [Abstract][Full Text] [Related]
15. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective.
Liang Z; Chen Q; Yang F; Yan X; Zhang X; Chen X; Fang F; Zhao Q
Cardiovasc Drugs Ther; 2021 Aug; 35(4):775-785. PubMed ID: 33090294
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
[TBL] [Abstract][Full Text] [Related]
18. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA
Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029
[TBL] [Abstract][Full Text] [Related]
19. Combined population genomic screening for three high-risk conditions in Australia: a modelling study.
Lacaze P; Marquina C; Tiller J; Brotchie A; Kang YJ; Merritt MA; Green RC; Watts GF; Nowak KJ; Manchanda R; Canfell K; James P; Winship I; McNeil JJ; Ademi Z
EClinicalMedicine; 2023 Dec; 66():102297. PubMed ID: 38192593
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
